The KinDex Pipeline

KinDex’s unique positioning is based on modulation of TAS2Rs, a group of GPCR receptors that influence endocrine and immune systems in multiple tissue types, including the small intestine, liver, lungs and gonads. Our most advanced candidate, KDT501 is an orally dosed small molecule that normalizes body weight and glucose and improves cyclicity, ovulation and testosterone levels in rodent models of metabolic disease and PCOS. We have successfully completed clinical Phase 1 safety, tolerability and PK studies of KDT501, as well as a 13-week monkey toxicology study and a Phase 2 proof-of-concept trial in metabolically disturbed patients. Our next goal is to study KDT501 in PCOS patients.

Our Pipeline

Indication Area Basic Research Pre-Clinical Phase 1 Phase 2 Phase 3
KDT 501 Polycystic Ovary Syndrome (PCOS)          
KDT 501 NASH          
KDTA0B Isohumulone Analog Chemistry          
TAS2R pathway exploration, KDTC0D Diabetes, obesity            
2021 Kindex Pharmaceuticals, 265 Franklin Street, Suite 1702
Boston, MA 02110
Website by Big Step Consulting